Neogenomics (NEO) Receivables - Net (2010 - 2026)

Neogenomics (NEO) has 17 years of Receivables - Net data on file, last reported at $175.4 million in Q2 2026.

• Quarterly Receivables - Net rose 14.55% year-over-year to $175.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $175.4 million (up 14.55% YoY) and the FY2025 annual result came in at $159.2 million, up 5.78% from the prior year.
• Receivables - Net grew to $175.4 million in Q2 2026, from $167.4 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $175.4 million in Q2 2026 to a low of $110.8 million in Q1 2022.
• A 5-year average of $139.6 million and a median of $143.4 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2023 — Receivables - Net rose 18.43% — and 2025, when it increased 2.55%.
• Tracing NEO's Receivables - Net over 5 years: stood at $119.7 million in 2022, then grew by 9.62% to $131.2 million in 2023, then grew by 14.72% to $150.5 million in 2024, then increased by 5.78% to $159.2 million in 2025, then gained by 10.15% to $175.4 million in 2026.
• The last three Receivables - Net figures came in at $175.4 million (Q2 2026), $167.4 million (Q1 2026), and $159.2 million (Q4 2025), per Business Quant data.